AP
IMNM icon

Antipodes Partners’s Immunome IMNM Stock Holding History

Antipodes Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Buy
7,971
+153
+2% +$3.27K ﹤0.01% 98
2026
Q1 		$171K Sell
7,818
-1,016
-12% -$22.6K ﹤0.01% 87
2025
Q4 		$190K Sell
8,834
-2,058
-19% -$36.1K ﹤0.01% 87
2025
Q3 		$128K Buy
10,892
+631
+6% +$6.28K ﹤0.01% 82
2025
Q2 		$95.4K Sell
10,261
-3,903
-28% -$32K ﹤0.01% 76
2025
Q1 		$95.3K Buy
+14,164
New +$136K ﹤0.01% 73

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Antipodes Partners's IMNM Position: Q2 2026 in Review

Antipodes Partners increased its Immunome (IMNM) stake by 2% in Q2 2026, buying an estimated $3.27K and bringing the position to 7,971 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #98.

Antipodes Partners first reported a position in IMNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $190K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Antipodes Partners held 7,971 shares of Immunome worth $169K as of Q2 2026.
  • Antipodes Partners bought 153 Immunome shares in Q2 2026, an estimated $3.27K.
  • Immunome made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #98 holding.
  • Antipodes Partners first reported a position in Immunome in Q1 2025 and has held it in 6 quarters since.
  • Antipodes Partners's Immunome position peaked at $190K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.